Skip Nav Destination
Issues
15 March 2012
-
Cover Image
Cover Image
IGFBP-5 may be an important regulator of IGF signaling in breast cancer cells. Distribution of IGFBP-5 in MCF-7 cells is shown by immunofluorescence analysis using confocal microscopy. IGFBP-5 is shown in red and nuclei are shown in blue (DAPI). For details, see the article by Becker and colleagues on page 1808 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Drug Approval
Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial
Martha Donoghue; Steven J. Lemery; Weishi Yuan; Kun He; Rajeshwari Sridhara; Stacy Shord; Hong Zhao; Anshu Marathe; Lori Kotch; Josephine Jee; Ying Wang; Liang Zhou; William M. Adams; Vaishali Jarral; Anne Pilaro; Richard Lostritto; Joseph E. Gootenberg; Patricia Keegan; Richard Pazdur
Molecular Pathways
CCR Focus
Review
Human Cancer Biology
Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics
Chien-Feng Li; Ju-Ming Wang; Hong-Yo Kang; Chiung-Kuei Huang; Jun-Wen Wang; Fu-Min Fang; Yu-Hui Wang; Wen-Ren Wu; Shau-Hsuan Li; Shih-Chen Yu; Jen-Chieh Lee; Jui Lan; Yow-Ling Shiue; Li-Ching Wu; Hsuan-Ying Huang
Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Gerwin Heller; Marlene Weinzierl; Christian Noll; Valerie Babinsky; Barbara Ziegler; Corinna Altenberger; Christoph Minichsdorfer; György Lang; Balazs Döme; Adelheid End-Pfützenreuter; Britt-Madeleine Arns; Yuliya Grin; Walter Klepetko; Christoph C. Zielinski; Sabine Zöchbauer-Müller
Cancer Therapy: Preclinical
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Osamu Takahashi; Ritsuko Komaki; Paul D. Smith; Juliane M. Jürgensmeier; Anderson Ryan; B. Nebiyou Bekele; Ignacio I. Wistuba; Jörg J. Jacoby; Maria V. Korshunova; Anna Biernacka; Baruch Erez; Keiko Hosho; Roy S. Herbst; Michael S. O'Reilly
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wei Wang; Qi Li; Shinji Takeuchi; Tadaaki Yamada; Hitomi Koizumi; Takahiro Nakamura; Kunio Matsumoto; Naofumi Mukaida; Yasuhiko Nishioka; Saburo Sone; Takayuki Nakagawa; Toshimitsu Uenaka; Seiji Yano
Imaging, Diagnosis, Prognosis
Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women
Nicolas Servant; Marc A. Bollet; Hans Halfwerk; Kevin Bleakley; Bas Kreike; Laurent Jacob; Daoud Sie; Ron M. Kerkhoven; Philippe Hupé; Rim Hadhri; Alain Fourquet; Harry Bartelink; Emmanuel Barillot; Brigitte Sigal-Zafrani; Marc J. van de Vijver
Cancer Therapy: Clinical
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L. Puhalla; Chandra P. Belani; David R. Gandara; Deborah Allen; Brian Kiesel; Jan H. Beumer; Edward M. Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J. Kinders; Ralph E. Parchment; Joseph E. Tomaszewski; James H. Doroshow
Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Nicolas Isambert; Gilles Freyer; Sylvie Zanetta; Benoît You; Pierre Fumoleau; Claire Falandry; Laure Favier; Sylvie Assadourian; Karen Soussan-Lazard; Samira Ziti-Ljajic; Veronique Trillet-Lenoir
Predictive Biomarkers and Personalized Medicine
KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
Claudia Miranda; Martina Nucifora; Francesca Molinari; Elena Conca; Maria Chiara Anania; Andrea Bordoni; Piercarlo Saletti; Luca Mazzucchelli; Silvana Pilotti; Marco A. Pierotti; Elena Tamborini; Angela Greco; Milo Frattini
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam; Argun Akcakanat; Huiqin Chen; Kim-Anh Do; Takafumi Sangai; Farrell Adkins; Ana Maria Gonzalez-Angulo; Asif Rashid; Katherine Crosby; Mei Dong; Alexandria T. Phan; Robert A. Wolff; Sanjay Gupta; Gordon B. Mills; James Yao
Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer
Quynh-Thu Le; Richard Fisher; Kelly S. Oliner; Richard J. Young; Hongbin Cao; Christina Kong; Edward Graves; Rodney J. Hicks; Grant A. McArthur; Lester Peters; Brian O'Sullivan; Amato Giaccia; Danny Rischin
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds